Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3,092 questions · 3,199 findings · 339 reviews · Headline outcomes only

No studies found 714 · 22.3%GRADE not reported 181 · 5.7%Very low 695 · 21.7%Low 908 · 28.4%Moderate 568 · 17.8%High 133 · 4.2%

Vitamin K antagonist (VKA) prophylaxis vs no prophylaxis

Mortality at 6 months: main analysis · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Vitamin K antagonist (VKA) prophylaxis showed no clear difference in mortality at 6 months: main analysis compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Vitamin K antagonist (VKA) prophylaxis vs no prophylaxis

All‐cause mortality · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Vitamin K antagonist (VKA) prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Vitamin K antagonist (VKA) prophylaxis vs no prophylaxis

Pulmonary embolism · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

It is very uncertain whether vitamin K antagonist (VKA) prophylaxis changes pulmonary embolism compared with no prophylaxis (very low certainty).

1 finding from 1 review

Vitamin K antagonist (VKA) prophylaxis vs no prophylaxis

Symptomatic DVT · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

It is very uncertain whether vitamin K antagonist (VKA) prophylaxis changes symptomatic deep vein thrombosis compared with no prophylaxis (very low certainty).

1 finding from 1 review